Log in to save to my catalogue

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1961839549

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a randomized trial involving more than 900 patients undergoing resection of advanced melanoma, adjuvant nivolumab was associated with a higher rate of 12-month recurrence-free survival than ipilimumab (70.5% vs. 60.8%) and with fewer adverse events.

Alternative Titles

Full title

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_1961839549

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1961839549

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1709030

How to access this item